# REDUCE LAP-HF TRIAL II

Study · id `cardio:ct-nct03088033` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03088033](<https://clinicaltrials.gov/study/NCT03088033>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03088033

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 608 participants.

## Technical summary

Registry record NCT03088033. Randomized; triple masking; primary purpose treatment. Start 2017-06-01 (actual); primary completion 2021-07-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 608 participants (planned count; ClinicalTrials.gov record NCT03088033, source copy `cardio:ctgov-nct03088033-2023-02-22`, retrieved 2026-10-26)
- Started: 2017-06-01 (actual) (ClinicalTrials.gov record NCT03088033, source copy `cardio:ctgov-nct03088033-2023-02-22`, retrieved 2026-10-26)
- Primary completion: 2021-07-29 (actual) (ClinicalTrials.gov record NCT03088033, source copy `cardio:ctgov-nct03088033-2023-02-22`, retrieved 2026-10-26)
- Completion: 2026-09 (anticipated) (ClinicalTrials.gov record NCT03088033, source copy `cardio:ctgov-nct03088033-2023-02-22`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Belgium; Canada; Croatia; Denmark; France; Germany; Italy; Japan; Netherlands; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT03088033, source copy `cardio:ctgov-nct03088033-2023-02-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03088033-2023-02-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: REDUCE LAP-HF TRIAL II
- Condition: Heart Failure
- Intervention (Device): IASD System II implant
- Intervention (Other): intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
- Lead sponsor: Corvia Medical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction (`cardio:pubmed-36939661`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction (`cardio:pubmed-37480877`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial (`cardio:pubmed-38630494`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II (`cardio:pubmed-38934964`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Expanded Definition of Worsening Heart Failure: Impact on Clinical Outcomes and Quality-of-Life Assessment (`cardio:pubmed-40714684`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II (`cardio:pubmed-42268170`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cd3b30a16f60f60287246a8f02888a93cd39995b97ea7799333330cc80d7c8cf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
